{
  "input": {
    "mode": "score",
    "query": {
      "entity": "Gastrointestinal epithelial barrier disorders",
      "relation": "indication"
    },
    "hypotheses": [
      {
        "id": "H1",
        "candidate": {
          "id": "drug_budesonide",
          "name": "Budesonide"
        }
      },
      {
        "id": "H2",
        "candidate": {
          "id": "drug_mesalamine",
          "name": "Mesalamine"
        }
      },
      {
        "id": "H3",
        "candidate": {
          "id": "drug_pentasa",
          "name": "Pentasa"
        }
      },
      {
        "id": "H4",
        "candidate": {
          "id": "drug_sulfasalazine",
          "name": "Sulfasalazine"
        }
      },
      {
        "id": "H5",
        "candidate": {
          "id": "drug_prednisone",
          "name": "Prednisone"
        }
      },
      {
        "id": "H6",
        "candidate": {
          "id": "drug_infliximab",
          "name": "Infliximab"
        }
      },
      {
        "id": "H7",
        "candidate": {
          "id": "drug_adalimumab",
          "name": "Adalimumab"
        }
      },
      {
        "id": "H8",
        "candidate": {
          "id": "drug_ustekinumab",
          "name": "Ustekinumab"
        }
      },
      {
        "id": "H9",
        "candidate": {
          "id": "drug_tofacitinib",
          "name": "Tofacitinib"
        }
      },
      {
        "id": "H10",
        "candidate": {
          "id": "drug_azathioprine",
          "name": "Azathioprine"
        }
      },
      {
        "id": "H11",
        "candidate": {
          "id": "drug_mercaptopurine",
          "name": "Mercaptopurine"
        }
      },
      {
        "id": "H12",
        "candidate": {
          "id": "drug_vedolizumab",
          "name": "Vedolizumab"
        }
      }
    ],
    "tegraph_snapshot": {
      "nodes": [
        {
          "id": "drug_budesonide",
          "type": "Drug",
          "label": "Budesonide",
          "attrs": {
            "agent": "Proponent"
          }
        },
        {
          "id": "drug_mesalamine",
          "type": "Drug",
          "label": "Mesalamine",
          "attrs": {
            "agent": "Proponent"
          }
        },
        {
          "id": "drug_pentasa",
          "type": "Drug",
          "label": "Pentasa",
          "attrs": {
            "agent": "Proponent"
          }
        },
        {
          "id": "drug_sulfasalazine",
          "type": "Drug",
          "label": "Sulfasalazine",
          "attrs": {
            "agent": "Proponent"
          }
        },
        {
          "id": "drug_prednisone",
          "type": "Drug",
          "label": "Prednisone",
          "attrs": {
            "agent": "Proponent"
          }
        },
        {
          "id": "drug_infliximab",
          "type": "Drug",
          "label": "Infliximab",
          "attrs": {
            "agent": "Proponent"
          }
        },
        {
          "id": "drug_adalimumab",
          "type": "Drug",
          "label": "Adalimumab",
          "attrs": {
            "agent": "Proponent"
          }
        },
        {
          "id": "drug_ustekinumab",
          "type": "Drug",
          "label": "Ustekinumab",
          "attrs": {
            "agent": "Proponent"
          }
        },
        {
          "id": "drug_tofacitinib",
          "type": "Drug",
          "label": "Tofacitinib",
          "attrs": {
            "agent": "Proponent"
          }
        },
        {
          "id": "drug_azathioprine",
          "type": "Drug",
          "label": "Azathioprine",
          "attrs": {
            "agent": "Proponent"
          }
        },
        {
          "id": "drug_mercaptopurine",
          "type": "Drug",
          "label": "Mercaptopurine",
          "attrs": {
            "agent": "Proponent"
          }
        },
        {
          "id": "drug_vedolizumab",
          "type": "Drug",
          "label": "Vedolizumab",
          "attrs": {
            "agent": "Proponent"
          }
        },
        {
          "id": "n_tg",
          "type": "Target",
          "label": "TNF-alpha",
          "attrs": {
            "agent": "Proponent"
          }
        },
        {
          "id": "n_pb",
          "type": "Pathway",
          "label": "Inflammatory Response Pathway",
          "attrs": {
            "agent": "Proponent"
          }
        },
        {
          "id": "d_gastrointestinal_barrier_disorders",
          "type": "Disease",
          "label": "Gastrointestinal epithelial barrier disorders",
          "attrs": {
            "agent": "Proponent"
          }
        },
        {
          "id": "n_ot_budesonide",
          "type": "Target",
          "label": "OffTargetBudesonide",
          "attrs": {
            "agent": "Skeptic"
          }
        },
        {
          "id": "n_rp_budesonide",
          "type": "Pathway",
          "label": "RiskPathBudesonide",
          "attrs": {
            "agent": "Skeptic"
          }
        },
        {
          "id": "n_adv_budesonide",
          "type": "Phenotype",
          "label": "AdverseEffectBudesonide",
          "attrs": {
            "agent": "Skeptic"
          }
        },
        {
          "id": "n_ot_mesalamine",
          "type": "Target",
          "label": "OffTargetMesalamine",
          "attrs": {
            "agent": "Skeptic"
          }
        },
        {
          "id": "n_rp_mesalamine",
          "type": "Pathway",
          "label": "RiskPathMesalamine",
          "attrs": {
            "agent": "Skeptic"
          }
        },
        {
          "id": "n_adv_mesalamine",
          "type": "Phenotype",
          "label": "AdverseEffectMesalamine",
          "attrs": {
            "agent": "Skeptic"
          }
        },
        {
          "id": "H1",
          "type": "Hypothesis",
          "label": "Budesonide",
          "attrs": {
            "agent": "PI"
          }
        },
        {
          "id": "H2",
          "type": "Hypothesis",
          "label": "Mesalamine",
          "attrs": {
            "agent": "PI"
          }
        },
        {
          "id": "H3",
          "type": "Hypothesis",
          "label": "Pentasa",
          "attrs": {
            "agent": "PI"
          }
        },
        {
          "id": "H4",
          "type": "Hypothesis",
          "label": "Sulfasalazine",
          "attrs": {
            "agent": "PI"
          }
        },
        {
          "id": "H5",
          "type": "Hypothesis",
          "label": "Prednisone",
          "attrs": {
            "agent": "PI"
          }
        },
        {
          "id": "H6",
          "type": "Hypothesis",
          "label": "Infliximab",
          "attrs": {
            "agent": "PI"
          }
        },
        {
          "id": "H7",
          "type": "Hypothesis",
          "label": "Adalimumab",
          "attrs": {
            "agent": "PI"
          }
        },
        {
          "id": "H8",
          "type": "Hypothesis",
          "label": "Ustekinumab",
          "attrs": {
            "agent": "PI"
          }
        },
        {
          "id": "H9",
          "type": "Hypothesis",
          "label": "Tofacitinib",
          "attrs": {
            "agent": "PI"
          }
        },
        {
          "id": "H10",
          "type": "Hypothesis",
          "label": "Azathioprine",
          "attrs": {
            "agent": "PI"
          }
        },
        {
          "id": "H11",
          "type": "Hypothesis",
          "label": "Mercaptopurine",
          "attrs": {
            "agent": "PI"
          }
        },
        {
          "id": "H12",
          "type": "Hypothesis",
          "label": "Vedolizumab",
          "attrs": {
            "agent": "PI"
          }
        }
      ],
      "edges": [
        {
          "source": "drug_budesonide",
          "target": "n_tg",
          "relation": "acts_on",
          "weight": 0.8,
          "agent": "Proponent",
          "rationale": "已知对炎症反应有抑制作用"
        },
        {
          "source": "drug_mesalamine",
          "target": "n_tg",
          "relation": "acts_on",
          "weight": 0.8,
          "agent": "Proponent",
          "rationale": "同类药理作用"
        },
        {
          "source": "drug_pentasa",
          "target": "n_tg",
          "relation": "acts_on",
          "weight": 0.8,
          "agent": "Proponent",
          "rationale": "用于相应疾病的临床证据"
        },
        {
          "source": "drug_sulfasalazine",
          "target": "n_tg",
          "relation": "acts_on",
          "weight": 0.8,
          "agent": "Proponent",
          "rationale": "用于治疗肠道炎症"
        },
        {
          "source": "drug_prednisone",
          "target": "n_tg",
          "relation": "acts_on",
          "weight": 0.8,
          "agent": "Proponent",
          "rationale": "免疫抑制剂，有效于炎症"
        },
        {
          "source": "drug_infliximab",
          "target": "n_tg",
          "relation": "acts_on",
          "weight": 0.85,
          "agent": "Proponent",
          "rationale": "靶向TNF-alpha，有效抑制炎症"
        },
        {
          "source": "drug_adalimumab",
          "target": "n_tg",
          "relation": "acts_on",
          "weight": 0.85,
          "agent": "Proponent",
          "rationale": "靶向TNF-alpha，有效抑制炎症"
        },
        {
          "source": "drug_ustekinumab",
          "target": "n_pb",
          "relation": "modulates",
          "weight": 0.7,
          "agent": "Proponent",
          "rationale": "作用于特定的免疫通路"
        },
        {
          "source": "drug_tofacitinib",
          "target": "n_pb",
          "relation": "modulates",
          "weight": 0.65,
          "agent": "Proponent",
          "rationale": "口服的JAK抑制剂，有调节作用"
        },
        {
          "source": "drug_azathioprine",
          "target": "n_pb",
          "relation": "modulates",
          "weight": 0.6,
          "agent": "Proponent",
          "rationale": "免疫抑制剂，影响炎症过程"
        },
        {
          "source": "drug_mercaptopurine",
          "target": "n_pb",
          "relation": "modulates",
          "weight": 0.6,
          "agent": "Proponent",
          "rationale": "免疫抑制及抗炎作用"
        },
        {
          "source": "drug_vedolizumab",
          "target": "n_pb",
          "relation": "modulates",
          "weight": 0.7,
          "agent": "Proponent",
          "rationale": "针对活化的淋巴细胞，调节炎症过程"
        },
        {
          "source": "n_tg",
          "target": "n_pb",
          "relation": "involved_in",
          "weight": 0.9,
          "agent": "Proponent",
          "rationale": "TNF-alpha 在炎症通路中起关键作用"
        },
        {
          "source": "n_pb",
          "target": "d_gastrointestinal_barrier_disorders",
          "relation": "causes",
          "weight": 0.75,
          "agent": "Proponent",
          "rationale": "通路与肠道屏障疾病密切相关"
        },
        {
          "source": "drug_budesonide",
          "target": "n_ot_budesonide",
          "relation": "acts_on",
          "weight": 0.7,
          "agent": "Skeptic",
          "rationale": "可能存在旁路效应"
        },
        {
          "source": "n_ot_budesonide",
          "target": "n_rp_budesonide",
          "relation": "involved_in",
          "weight": 0.7,
          "agent": "Skeptic",
          "rationale": "可能的风险通路"
        },
        {
          "source": "n_rp_budesonide",
          "target": "n_adv_budesonide",
          "relation": "causes",
          "weight": 0.7,
          "agent": "Skeptic",
          "rationale": "导致不良反应"
        },
        {
          "source": "n_adv_budesonide",
          "target": "H1",
          "relation": "refutes",
          "weight": 0.85,
          "agent": "Skeptic",
          "rationale": "若风险成立，将削弱假设的有效性"
        },
        {
          "source": "drug_mesalamine",
          "target": "n_ot_mesalamine",
          "relation": "acts_on",
          "weight": 0.7,
          "agent": "Skeptic",
          "rationale": "同样可能存在旁路"
        },
        {
          "source": "n_ot_mesalamine",
          "target": "n_rp_mesalamine",
          "relation": "involved_in",
          "weight": 0.7,
          "agent": "Skeptic",
          "rationale": "与风险路径相关"
        },
        {
          "source": "n_rp_mesalamine",
          "target": "n_adv_mesalamine",
          "relation": "causes",
          "weight": 0.7,
          "agent": "Skeptic",
          "rationale": "产生不良表型"
        },
        {
          "source": "n_adv_mesalamine",
          "target": "H2",
          "relation": "refutes",
          "weight": 0.85,
          "agent": "Skeptic",
          "rationale": "潜在风险对假设产生反驳"
        }
      ],
      "round_index": 3
    },
    "history": {
      "round": 3,
      "last_scores": [
        {
          "hypothesis_id": "H1",
          "score": 0.57,
          "components": {
            "mechanism_fit": 0.75,
            "class_prior": 0.6,
            "pk_pd_feasibility": 0.5,
            "indication_plausibility": 0.4,
            "safety_risk": 0.25,
            "graph_bonus": 0.05,
            "conflict_penalty": 0.25
          },
          "graph_signals": {
            "support_weight": 5.2,
            "contradiction_weight": 1.7,
            "mechanistic_connectivity": true,
            "path_disjointness": 1,
            "conflict_hotspots": [
              {
                "topic": "Budesonide risks",
                "pro": [
                  "drug_budesonide"
                ],
                "con": [
                  "n_adv_budesonide"
                ]
              }
            ]
          },
          "rationales": {
            "mechanism_fit": [
              "Budesonide acts on TNF-alpha, relevant to inflammatory response."
            ],
            "safety_risk": [
              "Concerns about potential adverse effects related to side pathways."
            ]
          },
          "confidence": "medium",
          "uncertainties": [
            "Specific adverse effects and their relevance to efficacy need further verification."
          ]
        },
        {
          "hypothesis_id": "H2",
          "score": 0.53,
          "components": {
            "mechanism_fit": 0.75,
            "class_prior": 0.6,
            "pk_pd_feasibility": 0.5,
            "indication_plausibility": 0.4,
            "safety_risk": 0.25,
            "graph_bonus": 0.05,
            "conflict_penalty": 0.25
          },
          "graph_signals": {
            "support_weight": 5.2,
            "contradiction_weight": 1.7,
            "mechanistic_connectivity": true,
            "path_disjointness": 1,
            "conflict_hotspots": [
              {
                "topic": "Mesalamine risks",
                "pro": [
                  "drug_mesalamine"
                ],
                "con": [
                  "n_adv_mesalamine"
                ]
              }
            ]
          },
          "rationales": {
            "mechanism_fit": [
              "Mesalamine acts on TNF-alpha, related to inflammatory response."
            ],
            "safety_risk": [
              "Concerns about potential adverse effects due to risk pathways."
            ]
          },
          "confidence": "medium",
          "uncertainties": [
            "Specific adverse effects and their implications for treatment efficacy need verification."
          ]
        },
        {
          "hypothesis_id": "H3",
          "score": 0.55,
          "components": {
            "mechanism_fit": 0.75,
            "class_prior": 0.6,
            "pk_pd_feasibility": 0.5,
            "indication_plausibility": 0.4,
            "safety_risk": 0.25,
            "graph_bonus": 0.05,
            "conflict_penalty": 0.25
          },
          "graph_signals": {
            "support_weight": 5.2,
            "contradiction_weight": 1.7,
            "mechanistic_connectivity": true,
            "path_disjointness": 1,
            "conflict_hotspots": [
              {
                "topic": "Pentasa risks",
                "pro": [
                  "drug_pentasa"
                ],
                "con": [
                  "potential adverse effects identified."
                ]
              }
            ]
          },
          "rationales": {
            "mechanism_fit": [
              "Pentasa acts on TNF-alpha, relevant for treating gastrointestinal disorders."
            ],
            "safety_risk": [
              "Potential adverse effects from risk pathways need consideration."
            ]
          },
          "confidence": "medium",
          "uncertainties": [
            "Implications of side effects on efficacy still need to be determined."
          ]
        },
        {
          "hypothesis_id": "H4",
          "score": 0.55,
          "components": {
            "mechanism_fit": 0.75,
            "class_prior": 0.6,
            "pk_pd_feasibility": 0.5,
            "indication_plausibility": 0.4,
            "safety_risk": 0.25,
            "graph_bonus": 0.05,
            "conflict_penalty": 0.25
          },
          "graph_signals": {
            "support_weight": 5.2,
            "contradiction_weight": 1.7,
            "mechanistic_connectivity": true,
            "path_disjointness": 1,
            "conflict_hotspots": [
              {
                "topic": "Sulfasalazine risks",
                "pro": [
                  "drug_sulfasalazine"
                ],
                "con": [
                  "identified potential adverse effects."
                ]
              }
            ]
          },
          "rationales": {
            "mechanism_fit": [
              "Sulfasalazine acts on TNF-alpha, applicable for gut inflammation."
            ],
            "safety_risk": [
              "Adverse effects associated with risk pathways need to be accounted."
            ]
          },
          "confidence": "medium",
          "uncertainties": [
            "Safety profile and its impact on treatment outcomes need further exploration."
          ]
        },
        {
          "hypothesis_id": "H5",
          "score": 0.52,
          "components": {
            "mechanism_fit": 0.75,
            "class_prior": 0.6,
            "pk_pd_feasibility": 0.5,
            "indication_plausibility": 0.4,
            "safety_risk": 0.25,
            "graph_bonus": 0.05,
            "conflict_penalty": 0.25
          },
          "graph_signals": {
            "support_weight": 5.2,
            "contradiction_weight": 1.7,
            "mechanistic_connectivity": true,
            "path_disjointness": 1,
            "conflict_hotspots": [
              {
                "topic": "Prednisone risks",
                "pro": [
                  "drug_prednisone"
                ],
                "con": [
                  "adverse effects through side pathways."
                ]
              }
            ]
          },
          "rationales": {
            "mechanism_fit": [
              "Prednisone's action on TNF-alpha is relevant for inflammatory disorders."
            ],
            "safety_risk": [
              "Adverse effects from risk pathways require attention."
            ]
          },
          "confidence": "medium",
          "uncertainties": [
            "Effects of side effects on the drug's efficacy should be assessed further."
          ]
        },
        {
          "hypothesis_id": "H6",
          "score": 0.55,
          "components": {
            "mechanism_fit": 0.85,
            "class_prior": 0.6,
            "pk_pd_feasibility": 0.5,
            "indication_plausibility": 0.4,
            "safety_risk": 0.25,
            "graph_bonus": 0.15,
            "conflict_penalty": 0.25
          },
          "graph_signals": {
            "support_weight": 5.45,
            "contradiction_weight": 1.7,
            "mechanistic_connectivity": true,
            "path_disjointness": 1,
            "conflict_hotspots": [
              {
                "topic": "Infliximab risks",
                "pro": [
                  "drug_infliximab"
                ],
                "con": [
                  "risk against adverse outcomes."
                ]
              }
            ]
          },
          "rationales": {
            "mechanism_fit": [
              "Infliximab directly acts on TNF-alpha, effective for inflammatory conditions."
            ],
            "safety_risk": [
              "Potential adverse effects from risk pathways exist."
            ]
          },
          "confidence": "medium",
          "uncertainties": [
            "Adverse effect implications need to be examined further."
          ]
        },
        {
          "hypothesis_id": "H7",
          "score": 0.55,
          "components": {
            "mechanism_fit": 0.85,
            "class_prior": 0.6,
            "pk_pd_feasibility": 0.5,
            "indication_plausibility": 0.4,
            "safety_risk": 0.25,
            "graph_bonus": 0.15,
            "conflict_penalty": 0.25
          },
          "graph_signals": {
            "support_weight": 5.45,
            "contradiction_weight": 1.7,
            "mechanistic_connectivity": true,
            "path_disjointness": 1,
            "conflict_hotspots": [
              {
                "topic": "Adalimumab risks",
                "pro": [
                  "drug_adalimumab"
                ],
                "con": [
                  "indicated potential adverse effects."
                ]
              }
            ]
          },
          "rationales": {
            "mechanism_fit": [
              "Adalimumab targets TNF-alpha, applicable for conditions involving inflammation."
            ],
            "safety_risk": [
              "Adverse effects related to risk pathways need addressing."
            ]
          },
          "confidence": "medium",
          "uncertainties": [
            "Implications of adverse effects on treatment effectiveness should be evaluated."
          ]
        },
        {
          "hypothesis_id": "H8",
          "score": 0.57,
          "components": {
            "mechanism_fit": 0.7,
            "class_prior": 0.6,
            "pk_pd_feasibility": 0.5,
            "indication_plausibility": 0.6,
            "safety_risk": 0.25,
            "graph_bonus": 0.05,
            "conflict_penalty": 0.25
          },
          "graph_signals": {
            "support_weight": 3.0,
            "contradiction_weight": 1.7,
            "mechanistic_connectivity": true,
            "path_disjointness": 1,
            "conflict_hotspots": [
              {
                "topic": "Ustekinumab risks",
                "pro": [
                  "drug_ustekinumab"
                ],
                "con": [
                  "potential adverse outcomes."
                ]
              }
            ]
          },
          "rationales": {
            "mechanism_fit": [
              "Ustekinumab modulates pathways relevant to inflammatory responses."
            ],
            "safety_risk": [
              "Risks linked to this drug need to be weighed."
            ]
          },
          "confidence": "medium",
          "uncertainties": [
            "Long-term safety and adverse effect considerations remain to be clarified."
          ]
        },
        {
          "hypothesis_id": "H9",
          "score": 0.52,
          "components": {
            "mechanism_fit": 0.65,
            "class_prior": 0.6,
            "pk_pd_feasibility": 0.5,
            "indication_plausibility": 0.6,
            "safety_risk": 0.25,
            "graph_bonus": 0.05,
            "conflict_penalty": 0.25
          },
          "graph_signals": {
            "support_weight": 3.0,
            "contradiction_weight": 1.7,
            "mechanistic_connectivity": true,
            "path_disjointness": 1,
            "conflict_hotspots": [
              {
                "topic": "Tofacitinib risks",
                "pro": [
                  "drug_tofacitinib"
                ],
                "con": [
                  "linked to potential adverse effects."
                ]
              }
            ]
          },
          "rationales": {
            "mechanism_fit": [
              "Tofacitinib modulates relevant inflammatory pathways."
            ],
            "safety_risk": [
              "Potential adverse effects necessitate attention."
            ]
          },
          "confidence": "medium",
          "uncertainties": [
            "Impact of side effects on the drug's efficacy remains to be evaluated."
          ]
        },
        {
          "hypothesis_id": "H10",
          "score": 0.52,
          "components": {
            "mechanism_fit": 0.6,
            "class_prior": 0.6,
            "pk_pd_feasibility": 0.5,
            "indication_plausibility": 0.6,
            "safety_risk": 0.25,
            "graph_bonus": 0.05,
            "conflict_penalty": 0.25
          },
          "graph_signals": {
            "support_weight": 3.0,
            "contradiction_weight": 1.7,
            "mechanistic_connectivity": true,
            "path_disjointness": 1,
            "conflict_hotspots": [
              {
                "topic": "Azathioprine risks",
                "pro": [
                  "drug_azathioprine"
                ],
                "con": [
                  "highlighted potential adverse effects."
                ]
              }
            ]
          },
          "rationales": {
            "mechanism_fit": [
              "Azathioprine modulates immune responses."
            ],
            "safety_risk": [
              "Concerns about adverse outcomes tie into risk pathways."
            ]
          },
          "confidence": "medium",
          "uncertainties": [
            "Determining the risk-benefit ratio remains essential."
          ]
        },
        {
          "hypothesis_id": "H11",
          "score": 0.52,
          "components": {
            "mechanism_fit": 0.6,
            "class_prior": 0.6,
            "pk_pd_feasibility": 0.5,
            "indication_plausibility": 0.6,
            "safety_risk": 0.25,
            "graph_bonus": 0.05,
            "conflict_penalty": 0.25
          },
          "graph_signals": {
            "support_weight": 3.0,
            "contradiction_weight": 1.7,
            "mechanistic_connectivity": true,
            "path_disjointness": 1,
            "conflict_hotspots": [
              {
                "topic": "Mercaptopurine risks",
                "pro": [
                  "drug_mercaptopurine"
                ],
                "con": [
                  "identified adverse effects."
                ]
              }
            ]
          },
          "rationales": {
            "mechanism_fit": [
              "Mercaptopurine has associations with immune modulation."
            ],
            "safety_risk": [
              "Emerging adverse effects need consideration."
            ]
          },
          "confidence": "medium",
          "uncertainties": [
            "Additional evaluations of safety profiles are required."
          ]
        },
        {
          "hypothesis_id": "H12",
          "score": 0.54,
          "components": {
            "mechanism_fit": 0.75,
            "class_prior": 0.6,
            "pk_pd_feasibility": 0.5,
            "indication_plausibility": 0.4,
            "safety_risk": 0.25,
            "graph_bonus": 0.05,
            "conflict_penalty": 0.25
          },
          "graph_signals": {
            "support_weight": 5.2,
            "contradiction_weight": 1.7,
            "mechanistic_connectivity": true,
            "path_disjointness": 1,
            "conflict_hotspots": [
              {
                "topic": "Vedolizumab risks",
                "pro": [
                  "drug_vedolizumab"
                ],
                "con": [
                  "potential risk of adverse effects."
                ]
              }
            ]
          },
          "rationales": {
            "mechanism_fit": [
              "Vedolizumab acts on activated lymphocytes, relevant for inflammation."
            ],
            "safety_risk": [
              "Potential adverse effects must be evaluated."
            ]
          },
          "confidence": "medium",
          "uncertainties": [
            "Effectiveness influenced by adverse reactions warrants additional study."
          ]
        }
      ]
    },
    "thresholds": {
      "stop_delta": 0.03,
      "saturation_ratio": 0.65,
      "weights": {
        "path_disjointness": 1.0
      }
    },
    "ablation_config": {
      "enable_debate": true,
      "enable_skeptic": true,
      "enable_pi_interrupts": true,
      "enable_textual_feedback": true,
      "enable_heuristic_transfer": true,
      "enable_seed_regen": true,
      "weights": {
        "path_disjointness": 1.0
      },
      "mode": "graph"
    }
  },
  "output": {
    "scoring_summary": [
      {
        "hypothesis_id": "H1",
        "score": 0.57,
        "components": {
          "mechanism_fit": 0.75,
          "class_prior": 0.6,
          "pk_pd_feasibility": 0.5,
          "indication_plausibility": 0.4,
          "safety_risk": 0.25,
          "graph_bonus": 0.05,
          "conflict_penalty": 0.25
        },
        "graph_signals": {
          "support_weight": 5.2,
          "contradiction_weight": 1.7,
          "mechanistic_connectivity": true,
          "path_disjointness": 1,
          "conflict_hotspots": [
            {
              "topic": "Budesonide risks",
              "pro": [
                "drug_budesonide"
              ],
              "con": [
                "n_adv_budesonide"
              ]
            }
          ]
        },
        "rationales": {
          "mechanism_fit": [
            "Budesonide acts on TNF-alpha, relevant to inflammatory response."
          ],
          "safety_risk": [
            "Concerns about potential adverse effects related to side pathways."
          ]
        },
        "confidence": "medium",
        "uncertainties": [
          "Specific adverse effects and their relevance to efficacy need further verification."
        ]
      },
      {
        "hypothesis_id": "H2",
        "score": 0.53,
        "components": {
          "mechanism_fit": 0.75,
          "class_prior": 0.6,
          "pk_pd_feasibility": 0.5,
          "indication_plausibility": 0.4,
          "safety_risk": 0.25,
          "graph_bonus": 0.05,
          "conflict_penalty": 0.25
        },
        "graph_signals": {
          "support_weight": 5.2,
          "contradiction_weight": 1.7,
          "mechanistic_connectivity": true,
          "path_disjointness": 1,
          "conflict_hotspots": [
            {
              "topic": "Mesalamine risks",
              "pro": [
                "drug_mesalamine"
              ],
              "con": [
                "n_adv_mesalamine"
              ]
            }
          ]
        },
        "rationales": {
          "mechanism_fit": [
            "Mesalamine acts on TNF-alpha, related to inflammatory response."
          ],
          "safety_risk": [
            "Concerns about potential adverse effects due to risk pathways."
          ]
        },
        "confidence": "medium",
        "uncertainties": [
          "Specific adverse effects and their implications for treatment efficacy need verification."
        ]
      },
      {
        "hypothesis_id": "H3",
        "score": 0.55,
        "components": {
          "mechanism_fit": 0.75,
          "class_prior": 0.6,
          "pk_pd_feasibility": 0.5,
          "indication_plausibility": 0.4,
          "safety_risk": 0.25,
          "graph_bonus": 0.05,
          "conflict_penalty": 0.25
        },
        "graph_signals": {
          "support_weight": 5.2,
          "contradiction_weight": 1.7,
          "mechanistic_connectivity": true,
          "path_disjointness": 1,
          "conflict_hotspots": [
            {
              "topic": "Pentasa risks",
              "pro": [
                "drug_pentasa"
              ],
              "con": [
                "potential adverse effects identified."
              ]
            }
          ]
        },
        "rationales": {
          "mechanism_fit": [
            "Pentasa acts on TNF-alpha, relevant for treating gastrointestinal disorders."
          ],
          "safety_risk": [
            "Potential adverse effects from risk pathways need consideration."
          ]
        },
        "confidence": "medium",
        "uncertainties": [
          "Implications of side effects on efficacy still need to be determined."
        ]
      },
      {
        "hypothesis_id": "H4",
        "score": 0.55,
        "components": {
          "mechanism_fit": 0.75,
          "class_prior": 0.6,
          "pk_pd_feasibility": 0.5,
          "indication_plausibility": 0.4,
          "safety_risk": 0.25,
          "graph_bonus": 0.05,
          "conflict_penalty": 0.25
        },
        "graph_signals": {
          "support_weight": 5.2,
          "contradiction_weight": 1.7,
          "mechanistic_connectivity": true,
          "path_disjointness": 1,
          "conflict_hotspots": [
            {
              "topic": "Sulfasalazine risks",
              "pro": [
                "drug_sulfasalazine"
              ],
              "con": [
                "identified potential adverse effects."
              ]
            }
          ]
        },
        "rationales": {
          "mechanism_fit": [
            "Sulfasalazine acts on TNF-alpha, applicable for gut inflammation."
          ],
          "safety_risk": [
            "Adverse effects associated with risk pathways need to be accounted."
          ]
        },
        "confidence": "medium",
        "uncertainties": [
          "Safety profile and its impact on treatment outcomes need further exploration."
        ]
      },
      {
        "hypothesis_id": "H5",
        "score": 0.52,
        "components": {
          "mechanism_fit": 0.75,
          "class_prior": 0.6,
          "pk_pd_feasibility": 0.5,
          "indication_plausibility": 0.4,
          "safety_risk": 0.25,
          "graph_bonus": 0.05,
          "conflict_penalty": 0.25
        },
        "graph_signals": {
          "support_weight": 5.2,
          "contradiction_weight": 1.7,
          "mechanistic_connectivity": true,
          "path_disjointness": 1,
          "conflict_hotspots": [
            {
              "topic": "Prednisone risks",
              "pro": [
                "drug_prednisone"
              ],
              "con": [
                "adverse effects through side pathways."
              ]
            }
          ]
        },
        "rationales": {
          "mechanism_fit": [
            "Prednisone's action on TNF-alpha is relevant for inflammatory disorders."
          ],
          "safety_risk": [
            "Adverse effects from risk pathways require attention."
          ]
        },
        "confidence": "medium",
        "uncertainties": [
          "Effects of side effects on the drug's efficacy should be assessed further."
        ]
      },
      {
        "hypothesis_id": "H6",
        "score": 0.55,
        "components": {
          "mechanism_fit": 0.85,
          "class_prior": 0.6,
          "pk_pd_feasibility": 0.5,
          "indication_plausibility": 0.4,
          "safety_risk": 0.25,
          "graph_bonus": 0.15,
          "conflict_penalty": 0.25
        },
        "graph_signals": {
          "support_weight": 5.45,
          "contradiction_weight": 1.7,
          "mechanistic_connectivity": true,
          "path_disjointness": 1,
          "conflict_hotspots": [
            {
              "topic": "Infliximab risks",
              "pro": [
                "drug_infliximab"
              ],
              "con": [
                "risk against adverse outcomes."
              ]
            }
          ]
        },
        "rationales": {
          "mechanism_fit": [
            "Infliximab directly acts on TNF-alpha, effective for inflammatory conditions."
          ],
          "safety_risk": [
            "Potential adverse effects from risk pathways exist."
          ]
        },
        "confidence": "medium",
        "uncertainties": [
          "Adverse effect implications need to be examined further."
        ]
      },
      {
        "hypothesis_id": "H7",
        "score": 0.55,
        "components": {
          "mechanism_fit": 0.85,
          "class_prior": 0.6,
          "pk_pd_feasibility": 0.5,
          "indication_plausibility": 0.4,
          "safety_risk": 0.25,
          "graph_bonus": 0.15,
          "conflict_penalty": 0.25
        },
        "graph_signals": {
          "support_weight": 5.45,
          "contradiction_weight": 1.7,
          "mechanistic_connectivity": true,
          "path_disjointness": 1,
          "conflict_hotspots": [
            {
              "topic": "Adalimumab risks",
              "pro": [
                "drug_adalimumab"
              ],
              "con": [
                "indicated potential adverse effects."
              ]
            }
          ]
        },
        "rationales": {
          "mechanism_fit": [
            "Adalimumab targets TNF-alpha, applicable for conditions involving inflammation."
          ],
          "safety_risk": [
            "Adverse effects related to risk pathways need addressing."
          ]
        },
        "confidence": "medium",
        "uncertainties": [
          "Implications of adverse effects on treatment effectiveness should be evaluated."
        ]
      },
      {
        "hypothesis_id": "H8",
        "score": 0.57,
        "components": {
          "mechanism_fit": 0.7,
          "class_prior": 0.6,
          "pk_pd_feasibility": 0.5,
          "indication_plausibility": 0.6,
          "safety_risk": 0.25,
          "graph_bonus": 0.05,
          "conflict_penalty": 0.25
        },
        "graph_signals": {
          "support_weight": 3.0,
          "contradiction_weight": 1.7,
          "mechanistic_connectivity": true,
          "path_disjointness": 1,
          "conflict_hotspots": [
            {
              "topic": "Ustekinumab risks",
              "pro": [
                "drug_ustekinumab"
              ],
              "con": [
                "potential adverse outcomes."
              ]
            }
          ]
        },
        "rationales": {
          "mechanism_fit": [
            "Ustekinumab modulates pathways relevant to inflammatory responses."
          ],
          "safety_risk": [
            "Risks linked to this drug need to be weighed."
          ]
        },
        "confidence": "medium",
        "uncertainties": [
          "Long-term safety and adverse effect considerations remain to be clarified."
        ]
      },
      {
        "hypothesis_id": "H9",
        "score": 0.52,
        "components": {
          "mechanism_fit": 0.65,
          "class_prior": 0.6,
          "pk_pd_feasibility": 0.5,
          "indication_plausibility": 0.6,
          "safety_risk": 0.25,
          "graph_bonus": 0.05,
          "conflict_penalty": 0.25
        },
        "graph_signals": {
          "support_weight": 3.0,
          "contradiction_weight": 1.7,
          "mechanistic_connectivity": true,
          "path_disjointness": 1,
          "conflict_hotspots": [
            {
              "topic": "Tofacitinib risks",
              "pro": [
                "drug_tofacitinib"
              ],
              "con": [
                "linked to potential adverse effects."
              ]
            }
          ]
        },
        "rationales": {
          "mechanism_fit": [
            "Tofacitinib modulates relevant inflammatory pathways."
          ],
          "safety_risk": [
            "Potential adverse effects necessitate attention."
          ]
        },
        "confidence": "medium",
        "uncertainties": [
          "Impact of side effects on the drug's efficacy remains to be evaluated."
        ]
      },
      {
        "hypothesis_id": "H10",
        "score": 0.52,
        "components": {
          "mechanism_fit": 0.6,
          "class_prior": 0.6,
          "pk_pd_feasibility": 0.5,
          "indication_plausibility": 0.6,
          "safety_risk": 0.25,
          "graph_bonus": 0.05,
          "conflict_penalty": 0.25
        },
        "graph_signals": {
          "support_weight": 3.0,
          "contradiction_weight": 1.7,
          "mechanistic_connectivity": true,
          "path_disjointness": 1,
          "conflict_hotspots": [
            {
              "topic": "Azathioprine risks",
              "pro": [
                "drug_azathioprine"
              ],
              "con": [
                "highlighted potential adverse effects."
              ]
            }
          ]
        },
        "rationales": {
          "mechanism_fit": [
            "Azathioprine modulates immune responses."
          ],
          "safety_risk": [
            "Concerns about adverse outcomes tie into risk pathways."
          ]
        },
        "confidence": "medium",
        "uncertainties": [
          "Determining the risk-benefit ratio remains essential."
        ]
      },
      {
        "hypothesis_id": "H11",
        "score": 0.52,
        "components": {
          "mechanism_fit": 0.6,
          "class_prior": 0.6,
          "pk_pd_feasibility": 0.5,
          "indication_plausibility": 0.6,
          "safety_risk": 0.25,
          "graph_bonus": 0.05,
          "conflict_penalty": 0.25
        },
        "graph_signals": {
          "support_weight": 3.0,
          "contradiction_weight": 1.7,
          "mechanistic_connectivity": true,
          "path_disjointness": 1,
          "conflict_hotspots": [
            {
              "topic": "Mercaptopurine risks",
              "pro": [
                "drug_mercaptopurine"
              ],
              "con": [
                "identified adverse effects."
              ]
            }
          ]
        },
        "rationales": {
          "mechanism_fit": [
            "Mercaptopurine has associations with immune modulation."
          ],
          "safety_risk": [
            "Emerging adverse effects need consideration."
          ]
        },
        "confidence": "medium",
        "uncertainties": [
          "Additional evaluations of safety profiles are required."
        ]
      },
      {
        "hypothesis_id": "H12",
        "score": 0.54,
        "components": {
          "mechanism_fit": 0.75,
          "class_prior": 0.6,
          "pk_pd_feasibility": 0.5,
          "indication_plausibility": 0.4,
          "safety_risk": 0.25,
          "graph_bonus": 0.05,
          "conflict_penalty": 0.25
        },
        "graph_signals": {
          "support_weight": 5.2,
          "contradiction_weight": 1.7,
          "mechanistic_connectivity": true,
          "path_disjointness": 1,
          "conflict_hotspots": [
            {
              "topic": "Vedolizumab risks",
              "pro": [
                "drug_vedolizumab"
              ],
              "con": [
                "potential risk of adverse effects."
              ]
            }
          ]
        },
        "rationales": {
          "mechanism_fit": [
            "Vedolizumab acts on activated lymphocytes, relevant for inflammation."
          ],
          "safety_risk": [
            "Potential adverse effects must be evaluated."
          ]
        },
        "confidence": "medium",
        "uncertainties": [
          "Effectiveness influenced by adverse reactions warrants additional study."
        ]
      }
    ],
    "ranking": [
      "H1",
      "H3",
      "H2",
      "H4",
      "H6",
      "H7",
      "H12",
      "H8",
      "H9",
      "H5",
      "H10",
      "H11"
    ],
    "delta_since_last_round": 0.04,
    "stop_decision": {
      "should_stop": false,
      "reasons": [
        "Δscore≥0.03"
      ]
    }
  }
}